RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Amphastar Pharmaceuticals Stock

Amphastar Pharmaceuticals Net Income 2024

Amphastar Pharmaceuticals Net Income

197.07 M USD

Ticker

AMPH

ISIN

US03209R1032

WKN

A11664

In 2024, Amphastar Pharmaceuticals's profit amounted to 197.07 M USD, a 43.27% increase from the 137.55 M USD profit recorded in the previous year.

The Amphastar Pharmaceuticals Net Income history

YEARNET INCOME (undefined USD)
2030e119.67
2029e118.67
2028e125.13
2027e319.27
2026e254.82
2025e223.15
2024e197.07
2023137.55
202291.4
202162.1
20201.4
201948.9
2018-5.7
20173.6
20169.8
2015-2.8
2014-10.7
201311.9
201218.1
20117.8
2010-10.7
2009-15.1

Amphastar Pharmaceuticals Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Amphastar Pharmaceuticals, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Amphastar Pharmaceuticals from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Amphastar Pharmaceuticals’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Amphastar Pharmaceuticals. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Amphastar Pharmaceuticals’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Amphastar Pharmaceuticals’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Amphastar Pharmaceuticals’s growth potential.

Amphastar Pharmaceuticals Revenue, EBIT and net profit per share

DateAmphastar Pharmaceuticals RevenueAmphastar Pharmaceuticals EBITAmphastar Pharmaceuticals Net Income
2030e728.28 M undefined179.32 M undefined119.67 M undefined
2029e714.31 M undefined176.87 M undefined118.67 M undefined
2028e693.29 M undefined172.89 M undefined125.13 M undefined
2027e1.16 B undefined462.37 M undefined319.27 M undefined
2026e865.53 M undefined318.32 M undefined254.82 M undefined
2025e794.15 M undefined279.31 M undefined223.15 M undefined
2024e760.64 M undefined260.13 M undefined197.07 M undefined
2023644.4 M undefined199.69 M undefined137.55 M undefined
2022499 M undefined107.5 M undefined91.4 M undefined
2021437.8 M undefined69.9 M undefined62.1 M undefined
2020349.8 M undefined11 M undefined1.4 M undefined
2019322.4 M undefined0 undefined48.9 M undefined
2018294.7 M undefined-8.6 M undefined-5.7 M undefined
2017240.2 M undefined-3.9 M undefined3.6 M undefined
2016255.2 M undefined15.4 M undefined9.8 M undefined
2015251.5 M undefined-6.7 M undefined-2.8 M undefined
2014210.5 M undefined-17.6 M undefined-10.7 M undefined
2013229.7 M undefined17.6 M undefined11.9 M undefined
2012204.3 M undefined27.5 M undefined18.1 M undefined
2011118.4 M undefined-33.4 M undefined7.8 M undefined
2010130.7 M undefined-6.2 M undefined-10.7 M undefined
2009148.6 M undefined3.8 M undefined-15.1 M undefined

Amphastar Pharmaceuticals stock margins

The Amphastar Pharmaceuticals margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Amphastar Pharmaceuticals. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Amphastar Pharmaceuticals.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Amphastar Pharmaceuticals's sales revenue. A higher gross margin percentage indicates that the Amphastar Pharmaceuticals retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Amphastar Pharmaceuticals's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Amphastar Pharmaceuticals's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Amphastar Pharmaceuticals's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Amphastar Pharmaceuticals. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Amphastar Pharmaceuticals's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Amphastar Pharmaceuticals Margin History

Amphastar Pharmaceuticals Gross marginAmphastar Pharmaceuticals Profit marginAmphastar Pharmaceuticals EBIT marginAmphastar Pharmaceuticals Profit margin
2030e54.91 %24.62 %16.43 %
2029e54.91 %24.76 %16.61 %
2028e54.91 %24.94 %18.05 %
2027e54.91 %39.79 %27.48 %
2026e54.91 %36.78 %29.44 %
2025e54.91 %35.17 %28.1 %
2024e54.91 %34.2 %25.91 %
202354.91 %30.99 %21.34 %
202249.88 %21.54 %18.32 %
202145.61 %15.97 %14.18 %
202040.97 %3.14 %0.4 %
201940.91 %0 %15.17 %
201836.31 %-2.92 %-1.93 %
201737.68 %-1.62 %1.5 %
201640.83 %6.03 %3.84 %
201530.74 %-2.66 %-1.11 %
201424.37 %-8.36 %-5.08 %
201337.88 %7.66 %5.18 %
201244.2 %13.46 %8.86 %
201123.73 %-28.21 %6.59 %
201038.41 %-4.74 %-8.19 %
200939.1 %2.56 %-10.16 %

Amphastar Pharmaceuticals Aktienanalyse

What does Amphastar Pharmaceuticals do?

Amphastar Pharmaceuticals Inc is a leading biopharmaceutical company that focuses on the development, manufacturing, and marketing of generic and innovative drugs. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California. History Amphastar Pharmaceuticals has a remarkable history in the generic industry. The company was founded by Dr. Jack Y. Zhang and Dr. Zhaocheng Guo, both of whom had doctorates in pharmacy. They initially worked as scientists at other pharmaceutical companies before deciding to start their own company. The beginning was difficult as they had limited financial resources and faced tough competition in the industry. However, the company grew through acquiring smaller competitors and developing its own products. Business Model Amphastar Pharmaceuticals' business model is based on the development, manufacturing, and marketing of generic drugs that meet medical needs. The company specializes in the treatment of diseases such as diabetes, heart disease, infections, and cancer. Utilizing unused patents and collaborations plays an important role in accessing new markets. Divisions Amphastar Pharmaceuticals is divided into three divisions: Human Pharmaceuticals, Veterinary Pharmaceuticals, and API (Active Pharmaceutical Ingredients). The Human Pharmaceuticals division specializes in developing products for the treatment of diseases such as diabetes, heart disease, infections, and cancer. The Veterinary Pharmaceuticals division focuses on developing veterinary drugs for livestock and pets. The API division is responsible for manufacturing raw materials for the pharmaceutical industry. Products Amphastar Pharmaceuticals offers a wide range of products, including inhalation aids for asthma, antidepressants, antidotes for anesthetics, anesthetics, drugs for cancer therapies, as well as for the treatment of HIV infections and nervous system disorders. In the field of veterinary products, Amphastar produces antibiotics, antifungals, vitamins, and hormones for animals. Conclusion Amphastar Pharmaceuticals Inc is a successful biopharmaceutical company specializing in the development, manufacturing, and marketing of generic and innovative drugs for a wide range of diseases. Since its inception, the company has been focused on growth and has continuously evolved through acquiring smaller competitors and developing its own products. The company offers a wide range of products for use in human and veterinary medicine and places special emphasis on providing high-quality drugs. Amphastar Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Net Income Details

Understanding Amphastar Pharmaceuticals's Profit Margins

The profit margins of Amphastar Pharmaceuticals represent the net income earned after deducting all operational expenses, costs, and taxes from the revenue. This figure is a clear indicator of Amphastar Pharmaceuticals's financial health, operational efficiency, and profitability. Higher profit margins signify better cost management and income generation capabilities.

Year-to-Year Comparison

Evaluating Amphastar Pharmaceuticals's profit on a yearly basis can offer significant insights into its financial growth, stability, and trends. A consistent increase in profit suggests improved operational efficiency, cost management, or increased revenue, while a decrease may indicate rising costs, declining sales, or operational challenges.

Impact on Investments

Amphastar Pharmaceuticals's profit figures are critical for investors who are aiming to understand the company's financial standing and future growth prospects. Increased profits often lead to higher stock valuations, boosting investor confidence and attracting more investments.

Interpreting Profit Fluctuations

When Amphastar Pharmaceuticals’s profit increases, it often indicates enhanced operational efficiency or increased sales. In contrast, a decline in profit can signal operational inefficiencies, increased costs, or competitive pressures, necessitating strategic interventions to boost profitability.

Frequently Asked Questions about Amphastar Pharmaceuticals stock

How much profit has Amphastar Pharmaceuticals made this year?

Amphastar Pharmaceuticals has made 197.07 M USD this year.

How has the profit developed compared to last year?

The profit has increased by 43.27% compared to last year increased

What impact do the earnings have on the shareholders?

An increase in earnings is usually seen as a positive indicator for shareholders as it means that the company is generating profits.

How does Amphastar Pharmaceuticals publish its earnings?

Amphastar Pharmaceuticals publishes its earnings in the form of quarterly or annual reports.

Which financial indicators are included in the quarterly or annual reports?

The quarterly or annual reports contain information about sales and profit, cash flow, balance sheet, and other fundamentals.

Why is it important for investors to know the earnings of Amphastar Pharmaceuticals?

The profits of Amphastar Pharmaceuticals are an important indicator of the financial health of the company and can help investors decide whether they want to invest in the company or not.

How can one learn more about the earnings of Amphastar Pharmaceuticals?

You can learn more about the earnings of Amphastar Pharmaceuticals by reviewing the quarterly or annual reports or following the company presentations.

How much dividend does Amphastar Pharmaceuticals pay?

Over the past 12 months, Amphastar Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Amphastar Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Amphastar Pharmaceuticals?

The current dividend yield of Amphastar Pharmaceuticals is .

When does Amphastar Pharmaceuticals pay dividends?

Amphastar Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Amphastar Pharmaceuticals?

Amphastar Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Amphastar Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Amphastar Pharmaceuticals located?

Amphastar Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Amphastar Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Amphastar Pharmaceuticals from 10/2/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/2/2024.

When did Amphastar Pharmaceuticals pay the last dividend?

The last dividend was paid out on 10/2/2024.

What was the dividend of Amphastar Pharmaceuticals in the year 2023?

In the year 2023, Amphastar Pharmaceuticals distributed 0 USD as dividends.

In which currency does Amphastar Pharmaceuticals pay out the dividend?

The dividends of Amphastar Pharmaceuticals are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Amphastar Pharmaceuticals

Our stock analysis for Amphastar Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Amphastar Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.